ATAlbert Tiong

Albert Tiong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Albert Tiong has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach

    by Jasper de Boer, Rebecca Barnett, Anthony Cardin, Michelle Cimoli, Lauren Davies, Clare Delany, Benjamin J. Dixon, Sue M. Evans, Michael W. Findlay, Carly Fox, et al.

    A multidisciplinary approach to the management of tongue cancer is vital for achieving optimal patient outcomes. Nursing and allied health professionals play essential roles within the team. We developed symposia comprising a series of online lectures offering a detailed perspective on the role each discipline and consumer perspective has in the management of patients with tongue cancer. The topics, including epidemiology and prevention, diagnosis, treatment planning, surgery, adjuvant care, and the management of recurrent or metastatic disease, were thoroughly examined. The symposia highlighted the significance of fostering collaboration and continuous learning through a multidisciplinary approach. This initiative should be relevant to healthcare professionals, researchers, and policymakers striving to enhance patient outcomes in tongue cancer care through innovative collaboration.


  • Open Access

    Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors

    by Nicholas W Bucknell, David E Gyorki, Mathias Bressel, Vanessa Estall, Angela Webb, Michael Henderson, Margaret S‐T Chua, Danny Rischin, Albert Tiong

    Purpose: This study examined the clinical outcomes and prognostic factors of patients with metastatic cutaneous SCC metastatic to the axilla and groin when managed with curative‐intent lymphadenectomy and received (neo)adjuvant treatment.Methods and Materials: We conducted a single institution retrospective review. Patients who had nodal disease without distant spread were 18 years or older with no non‐cutaneous primary identified.Results: From January 2000 to July 2015, 78 patients were treated for axilla (64, 82%) or inguinal (14, 18%) involvement with cSCC. The median age was 75.5 years (range: 29–95), and 8 patients (11%) were immunosuppressed. The median size of the largest node was 45 mm (range: 8–135), and extracapsular extension was found in 63 (81%) cases. A majority of patients were treated with surgery alone (21, 26.9%) and surgery with adjuvant radiation therapy (54, 69%). The 2‐year OS and PFS were 50% (95% CI: 40%–63%) and 43% (95% CI: 33%–56%), and 5‐year OS and PFS were 33% (95% CI:23%–47%) and 32% (95% CI:22%–46%) respectively in the entire cohort. On univariable analysis, factors associated with longer OS were as follows: younger age (HR 1.1, 95% CI: 0.9–1.3 P = 0.021), improved performance status (HR 1.5, 95% CI:1.0–2.3 P = 0.026), lack of immunosuppression (HR 3.3, 95% CI: 1.5–7.3 P = 0.001), lower lymph node ratio (HR 1.2, 95% CI:1.0–1.3 P = 0.007), lower number of positive nodes (HR 1.1, 95% CI:1.0–1.2 P = 0.004) and the use of radiation therapy (HR 0.5, 95% CI:0.3–0.9 P = 0.012).Conclusion: Metastasis to the axilla and groin with cSCC has poor outcomes with standard treatment. The addition of immunotherapy warrants investigation.


  • Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma

    by Christopher P. Daniels, Mathias Bressel, June Corry, Aidan Cole, Margaret S.-T. Chua, Albert Tiong, Nir Hirshoren, Ben Dixon, Lachlan McDowell


  • Unilateral radiotherapy treatment for p16/human papillomavirus–positive squamous cell carcinoma of unknown primary in the head and neck

    by Albert Tiong, Danny Rischin, Richard J. Young, Alan Herschtal, Ben Solomon, Ieta D'Costa, Tsien Fua, Chen Liu, Andrew Coleman, Stephen Kleid, et al.

    Objectives/Hypothesis: The outcomes of unilateral radiotherapy treatment for patients with p16/HPV‐positive squamous cell carcinomas of unknown primary (SCCUP) affecting cervical lymph nodes are under‐reported. Compared to radiating large volumes of the pharyngeal axis (the more common approach), this is potentially a much less toxic treatment for a good prognosis group.Study Design: Retrospective cohort study.Methods: We identified patients with SCCUP who were treated radically at our center and did not have parotid or isolated level IV or V nodal involvement. Failure‐free and overall survivals were calculated using Kaplan‐Meier methods.Results: From 2004 to 2012, there were 49 radically treated patients with SCCUP. Fourteen patients had bilateral neck treatment (they had bilateral nodal disease or suspected lesions in the base of tongue, though not proven with biopsy), two had surgery alone, whereas 33 had unilateral radiotherapy (after neck dissection, excisional biopsy, or definitively with concurrent chemotherapy). Of the 33 patients, 21 tested positive to p16/HPV and had median follow‐up of 57 months. In this group, no isolated contralateral neck failures or putative primaries emerged. There was 1/21 (4.3%) ipsilateral neck failure, 1/21 (4.3%) concurrent contralateral neck and distant failure, and 1/21 (4.3%) patient with distant failure. The 5‐year freedom from failure was 78% (95% confidence interval [CI]: 56%‐100%) and overall survival was 90% (95% CI: 79%‐100%).Conclusions: With no emergence of putative primaries and no isolated contralateral neck failures, this single‐institution experience in p16/HPV‐positive SCCUP patients suggests that unilateral radiotherapy may be an underutilized management strategy.Levels of Evidence: 4 Laryngoscope, 128:2076–2083, 2018


  • Faculty of Radiation Oncology Position Paper on the use of Image–Guided Radiation Therapy

    by Albert Tiong, Louis Lao, James MacKean, Madhavi Goonetilleke, Tomas Kron

    Summary: The development of technology such as intensity‐modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and stereotactic ablative body radiotherapy (SABR) has resulted in highly conformal radiotherapy treatments. While such technology has allowed for improved dose delivery, it has also meant that improved accuracy in the treatment room is required. Image‐guided radiotherapy (IGRT), the use of imaging prior to or during treatment delivery, has been shown to improve the accuracy of treatment delivery and in some circumstances, clinical outcomes. Allied with the adoption of highly conformal treatments, there is a need for stringent quality assurance processes in a multidisciplinary environment. In 2015, the Royal Australian and New Zealand College of Radiologist (RANZCR) updated its position paper on IGRT. The draft document was distributed through the membership of the Faculty of Radiation Oncology (FRO) for review and the final version was endorsed by the board of FRO. This article describes issues that radiotherapy departments throughout Australia and New Zealand should consider. It outlines the role of IGRT and reviews current clinical evidence supporting the benefit of IGRT in genitourinary, head and neck, and lung cancers. It also highlights important international publications which provide guidance on implementation and quality assurances for IGRT. A set of key recommendations are provided to guide safe and effective IGRT implementation and practice in the Australian and New Zealander context.


  • Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma

    by Damien Urban, June Corry, Ben Solomon, Annette M. Lim, Tsien Fua, Andrew Coleman, Ieta D'Costa, Albert Tiong, Chen Liu, Lester J. Peters, et al.

    Background There is interest in different treatment strategies, including deintensification in good prognosis human papillomavirus‐positive (HPV(+)) oropharyngeal squamous cell carcinoma (SCC). We reviewed our experience with weekly cisplatin in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. Methods Data from patients with low‐risk HPV(+) oropharyngeal SCC treated with weekly cisplatin (40 mg/m2) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1‐2N1, T4 or N3 disease, or N2b to N2c disease in patients with >10 pack‐year smoking history. Results Of 31 patients, the median age was 56 years (range, 41–69 years). All patients completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of cisplatin. Grade 3 mucositis occurred in 22 patients (71%) and grade 3 febrile neutropenia in 6 patients (19%). No patients required enteral feeding at 12 months. The median follow‐up was 30 months (range, 21–57 months) with no recurrences or deaths. Conclusion Concurrent weekly cisplatin is relatively well‐tolerated and associated with excellent disease control in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1117–E1121, 2016